Related Experiment Video
Updated: Sep 28, 2025
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Valosin Containing Protein as a Specific Biomarker for Predicting the Development of Acute Coronary Syndrome and Its
Chenchao Xu1, Bokang Yu1, Xin Zhao2
1Department of Forensic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Insights
Serum Valosin-containing protein (VCP) is a stable biomarker for predicting acute coronary syndrome (ACS) and its complication, ventricular dysfunction (VD). Higher VCP levels indicate ACS risk, while lower levels suggest VD development in ACS patients.
Area of Science:
- Cardiology
- Biomarker Discovery
- Genetics
Background:
- Acute coronary syndrome (ACS) is linked to ventricular dysfunction (VD) and heart failure.
- Current indicators for ACS development and prognosis are insufficient.
- Valosin-containing protein (VCP) shows potential cardioprotective effects.
Purpose of the Study:
- To evaluate serum VCP as a predictive biomarker for ACS.
- To assess VCP's role in predicting the complication of VD in ACS patients.
Main Methods:
- Serum samples from 291 participants (controls, ACS, CCS, non-IHD) were analyzed using ELISA for VCP levels.
- Statistical analysis, including multivariate logistic regression, was used to study the association of VCP with ACS and VD.
- Genome-wide association studies (GWAS) and expression quantitative trait loci (eQTL) analyses explored VCP polymorphism and monocyte count association.
- Serum VCP stability was tested under various conditions.
Main Results:
- Serum VCP levels were significantly elevated in the ACS group compared to other groups.
- Patients with ACS and VD exhibited lower serum VCP levels than those without VD.
- VCP was independently associated with increased ACS risk (OR=1.222) and decreased risk of VD in ACS patients (OR=0.513).
- A VCP polymorphism (rs684562) was linked to monocyte count, verified by eQTL analysis.
- Serum VCP demonstrated high stability.
Conclusions:
- Serum Valosin-containing protein (VCP) can serve as a stable biomarker for predicting ACS development.
- VCP is also a valuable biomarker for predicting ventricular dysfunction (VD) in patients with ACS.
- The findings support VCP's role in cardiac disease prediction and highlight potential genetic links.
Background:
Acute coronary syndrome (ACS) consists of a range of acute myocardial ischemia-related manifestations. The adverse events of ACS are usually associated with ventricular dysfunction (VD), which could finally develop to heart failure. Currently, there is no satisfactory indicator that could specifically predict the development of ACS and its prognosis. Valosin-containing protein (VCP) has recently been proposed to protect against cardiac diseases. Hence, we aimed to assess whether VCP in serum can serve as a valuable biomarker for predicting ACS and its complication.
Methods:
Human serum samples from 291 participants were collected and classified into four groups based on their clinical diagnosis, namely healthy control (n = 64), ACS (n = 40), chronic coronary syndrome (CCS, n = 99), and nonischemic heart disease (non-IHD, n = 88). Clinical characteristics of these participants were recorded and their serum VCP levels were detected by enzyme-linked immunosorbent assay (ELISA). Association of serum VCP with the development of ACS and its complication VD was statistically studied. Subsequently, GWAS and eQTL analyses were performed to explore the association between VCP polymorphism and monocyte count. A stability test was also performed to investigate whether VCP is a stable biomarker.
Results:
Serum VCP levels were significantly higher in the ACS group compared with the rest groups. Besides, the VCP levels of patients with ACS with VD were significantly lower compared to those without VD. Multivariate logistic regression analysis revealed that VCP was associated with both the risk of ACS (P = 0.042, OR = 1.222) and the risk of developing VD in patients with ACS (P = 0.035, OR = 0.513) independently. The GWAS analysis also identified an association between VCP polymorphism (rs684562) and monocyte count, whereas the influence of rs684562 on VCP mRNA expression level was further verified by eQTL analysis. Moreover, a high stability of serum VCP content was observed under different preservation circumstances.
Conclusion:
Valosin-containing protein could act as a stable biomarker in predicting the development of ACS and its complication VD.
More Related Videos
10:12A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
Published on: August 8, 2013
08:51Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:30Acute Coronary Syndrome I: Introduction
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:26Acute Coronary Syndrome V: Nursing Management